Surveillance of patients with chronic hepatitis C not on antiviral therapy: A practical approach

Romanian Journal of Gastroenterology

Volumn 14, Issue 2, 2005, Pages 141-146

  Puoti, Claudio ^a   Bellis, Lia ^a   Martellino, Francesca ^a   Durola, Laura ^a   Galossi, Alessandra ^a   Guarisco, Riccardo ^a   Dell'Unto, Orlando ^a  

^a Marino Hospital Rome   (Italy)

Author keywords

Aminotransferases; Follow up; HCV; Interferon

Indexed keywords

AMINOTRANSFERASE; INTERFERON;

COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; FOLLOW UP; HEALTH SURVEY; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; PRACTICE GUIDELINE; REVIEW; RISK;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); POPULATION SURVEILLANCE; RISK FACTORS;

EID: 21644465825     PISSN: 12214167     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology 1998; 27: 273-278.
2. Provenzale D. Economic considerations for hepatologist. Hepatology 199; 29: 13S-17S.
3. Strader DB, Wright T, Thomas DL, Seef LB. AASLD Practice Guideline. Diagnosis, management and treatment of Hepatitis C. Hepatology 2004; 39: 1147-1171.
4. Alberti A, Benvegnù L. Management of chronic hepatitis C. J Hepatol. 2003; 38 Suppl 1: S104-S118.
5. Porok PC. Epidemiologic approach for cancer screening. Problems in design and analysis of trials. Am J Pediatr Haematol Oncol 1992; 14: 117-128.
6. Shehab TM, Sonnad SS, Jeffries M, Gunaratnum N, Lok ASF. Current practice patterns of primary care physicians in the management of patients with hepatitis C. Hepatology 1999; 30: 794-800
7. American Gastroenterological Association (AGA) Technical review on the evaluation of Liver Chemistry Tests. Gastroenterology 2002; 123: 1367-1384.
8. Puoti C, Castellacci R., Montagnese F. Hepatitis C virus carriers with normal aminotransferase levels: healthy people or true patients? Digest Liver Dis 2000; 32: 634-643.
9. Puoti C, Castellacci R, Montagnese F, et al. Histological and virological features and follow-up of Hepatitis C Virus carriers with normal aminotran-sferase levels: The Italian Prospective Study of The Asympto-matic C Carriers (ISACC). J Hepatol 2002; 37: 117-123.
10. Bacon BR. Patients with normal ALT levels. NIH Consensus Development Conference Statement Management of Hepatitis C: 2002. Hepatology 2002; 36 (Suppl. ): S179-S184.
11. Martinot-Peignoux M, Boyer N, Cazals-Hatem D, et al. Perspective study of anti-hepatitis C virus-positive patients with persistently normal serum ALT with or without detectable serum HCV RNA. Hepatology 2001; 34: 1000-1005.
12. Puoti C, Magrini A, Stati T, et al. Clinical, histological and virological features of hepatitis C virus carriers with persistently normal aminotransferase levels. Hepatology 1997; 26: 1393-1398
13. Mathurin P, Moussali J, Cadranel JF, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998; 27: 868-872.
14. Zeuzem S, Diago M, Gane E, et al. Peginterferon alfa-2a (40KD) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127: 1724-32.
15. Marcellin P, Levy S, Erlinger S. Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology 1997; 26 (Suppl 1): 133S-136S.
16. Puoti C, Guido M, Mangia A, Persico M, Prati D. Clinical management of HCV carriers with normal aminotransferase levels. Dig Liver Dis 2003;35:362-9.
17. Puoti C. HCV carriers with normal ALT levels: not too much healthy, not true patients. Rom J Gastroenterol Hepatol 2004; 13: 329-332
18. Puoti C. HCV carriers with persistently normal aminotransferase levels: normal does not always mean healthy. J Hepatol 2003; 38: 529-532
19. Poynard T, Moussali J, Ratziu V, Regimbeau C, Opolon P. Effects of interferon therapy in non responders patients with chronic hepatitis C. J Hepatol 1999; 31 (Suppl. 1): 178-183.
20. Shiffman ML. Retreatment of patients with chronic hepatitis C. Hepatology 2002; 36 (Suppl. 1): S128-S134.
21. Lindsay K. Introduction to therapy of hepatitis C. Hepatology 2002; 36 (Suppl. 1): S114-S120.
22. Radkowski M, Gallegos-Orozco JF, Jablosnka J, et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 2005; 41: 106-114.
23. Di Bisceglie AM. Natural history of hepatitis C: its impact on clinical management. Hepatology 2000; 31: 1014-1017.
24. Khan MH, Farrell GC, Byth K, et al. Which patients with hepatitis C develop liver complications? Hepatology 2000; 31: 513-520.
25. de Franchis R. Evaluation and follow-up of patients with cirrhosis and esophageal varices. J Hepatol 2003; 38: 361-363.
26. Jensen DM. Endoscopic screening for varices in cirrhosis: findings, implications and outcomes. Gastroenterology 2002; 122: 1620-1630.
27. Pilette C, Oberti F, Aubé C, Rousselet M, Bedossa P. Non-invasive diagnosis of esophageal varices in chronic liver disease. J Hepatol 1999; 31: 867-873.
28. Schepis F, Cammà C, Niceforo D, Magnano A, Pallio S, Cinquegrani M et al. Which patients with cirrhosis should undergo endoscopic screening for esophageal varices detection? Hepatology 2001; 33: 333-338.
29. Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34: 809-816.
30. Streiff MB, Mehta Shrudi, Thomas DI. Peripheral blood count abnormalities among patients with Hepatitis C in the United States. Hepatology 2002; 35: 947-952.
31. Puoti C, Bellis L. Should (and could) we measure portal pressure in clinical practice? Gastro International 2002; 15: 51-57.
32. Llovet JM, Beaugrand M. Hepatocellular carcinoma: present status and future prospects. J Hepatol 2003; 38: S136-149.